Company profile
SAREPTA THERAPEUTICS, INC.
NASDAQ:SRPTBiotechnology: Pharmaceutical Preparations
Drug pipeline (9)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ELEVIDYS | approved | $98.1MQ2 2026 | 0 | — |
| AMONDYS 45 | approved | — | 1 | approved |
| EXONDYS 51 | approved | — | 8 | approved |
| VYONDYS 53 | approved | — | 3 | approved |
| BIDRIDISTROGENE XEBOPARVOVEC | phase3 | — | 3 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (49)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07536061 | phase1 | recruiting | 2026-05-12 | 2027-11-30 | Sarepta Therapeutics, Inc. | A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease |
| NCT05876780 | phase1 | active_not_recruiting | 2022-12-19 | 2028-08-28 | Sarepta Therapeutics, Inc. | A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency) |
| NCT05906251 | phase1 | terminated | 2023-05-22 | 2025-06-13 | Sarepta Therapeutics, Inc. | A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related) |
| NCT06241950 | phase1 | terminated | 2024-01-29 | 2025-10-10 | Sarepta Therapeutics, Inc. | A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74) |
| NCT05881408 | phase3 | active_not_recruiting | 2023-05-31 | 2027-05-31 | Sarepta Therapeutics, Inc. | A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) |
FDA applications (4)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 125781 | 2023-06-22 | BLA | SAREPTA THERAPEUTICS, INC. | |||||
Loading… | ||||||||
| NDA 213026 | 2021-02-25 | NDA | SAREPTA THERAPEUTICS INC | |||||
Loading… | ||||||||
| NDA 211970 | 2019-12-12 | NDA | SAREPTA THERAPEUTICS INC | |||||
Loading… | ||||||||
| NDA 206488 | 2016-09-19 | NDA | SAREPTA THERAPEUTICS INC | |||||
Loading… | ||||||||